In this issue:
Pretreatment emotional distress and neoadjuvant ICI blockade response
The features and management of AR to PD1 therapy
Trial of the CD40 agonistic antibody sotigalimab + nivolumab
Adjuvant nivolumab in resected stage IIB/C melanoma
The genetic risk of NM using a candidate gene approach
Risk factors for subsequent primary melanoma in patients with previous melanoma
Survival rates in patients diagnosed with MIS
The limited value of sentinel lymph node biopsy in lentigo malinga melanoma
Lower frequencies of circulating suppressive regulatory T cells with severe irAEs
Dabrafenib plus trametinib vs anti-PD1 for BRAF V600-mutant melanoma
Please login below to download this issue (PDF)